Changes to the Code
S. 1186 · Lower Drug Costs for Families Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1395w–3a Use of average sales price payment methodology
10 changes the bill asks for here, 10 carried out
- Carried out:
in paragraph (1)(A)(i), by striking
units
and insertingbilling units
; - Carried out:
in paragraph (2)(A), by striking
for which payment is made under this part
and insertingthat would be payable under this part if such drug were furnished to an individual enrolled under this part
; and - Carried out:
in subparagraph (A)(i), by striking
units
and insertingbilling units
; and - Carried out:
by striking subparagraph (B) and inserting the following:
(B) Total number of billing units.— For purposes of subparagraph (A)(i), the total number of billing units with respect to a part B rebatable drug is determined as follows: (i) Determine the total number of units equal to— (I) the total number of units, as reported under …
- Carried out:
in subparagraph (D), by striking
July 1, 2021
and insertingJuly 1, 2016
; and - Carried out:
in subparagraph (E), by striking
January 2021
and insertingJanuary 2016
; and - Carried out:
by striking
December 1, 2020
and insertingDecember 31, 2015
; and - Carried out:
by striking
January 2021
and insertingJanuary 2016
; - Carried out:
in subparagraph (B), by striking
December 1, 2020
and insertingDecember 31, 2015
; and - Carried out:
in subparagraph (C), by striking
January 2021
and insertingJanuary 2016
.
§ 1395w–3a(i)Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation(1)–(2)
Start of § 1395w–3a to (i)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(A) | (A) Secretarial provision of information | (A) Secretarial provision of information | ||
| Not later than 6 months after the end of each calendar quarter beginning on or after January 1, 2023, the Secretary shall, for each part B rebatable drug, report to each manufacturer of such part B rebatable drug the following for such calendar quarter: | Not later than 6 months after the end of each calendar quarter beginning on or after January 1, 2023, the Secretary shall, for each part B rebatable drug, report to each manufacturer of such part B rebatable drug the following for such calendar quarter: | |||
| (1)(A)(i) | (i) | (i) | ||
| Information on the total number of units of the billing and payment code described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter. | Information on the total number of [inserted: billing ]units of the billing and payment code described in subparagraph (A)(i) of paragraph (3) with respect to such drug and calendar quarter. | |||
| (1)(A)(ii) | (ii) | (ii) | ||
| Information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter. | Information on the amount (if any) of the excess average sales price increase described in subparagraph (A)(ii) of such paragraph for such drug and calendar quarter. | |||
| (1)(A)(iii) | (iii) | (iii) | ||
| The rebate amount specified under such paragraph for such part B rebatable drug and calendar quarter. | The rebate amount specified under such paragraph for such part B rebatable drug and calendar quarter. | |||
| (1)(B) | (B) Manufacturer requirement | (B) Manufacturer requirement | ||
| For each calendar quarter beginning on or after January 1, 2023, the manufacturer of a part B rebatable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter. | For each calendar quarter beginning on or after January 1, 2023, the manufacturer of a part B rebatable drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in paragraph (3) for such drug for such calendar quarter. | |||
| (1)(C) | (C) Transition rule for reporting | (C) Transition rule for reporting | ||
| The Secretary may, for each part B rebatable drug, delay the timeframe for reporting the information described in subparagraph (A) for calendar quarters beginning in 2023 and 2024 until not later than September 30, 2025. | The Secretary may, for each part B rebatable drug, delay the timeframe for reporting the information described in subparagraph (A) for calendar quarters beginning in 2023 and 2024 until not later than September 30, 2025. | |||
| (2) | (2) Part B rebatable drug defined | (2) Part B rebatable drug defined | ||
| (2)(A) | (A) In general | (A) In general | ||
| In this subsection, the term “part B rebatable drug” means a single source drug or biological (as defined in subparagraph (D) of subsection (c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such subsection) but excluding a qualifying biosimilar biological product (as defined in subsection (b)(8)(B)(iii)), | In this subsection, the term “part B rebatable drug” means a single source drug or biological (as defined in subparagraph (D) of subsection (c)(6)), including a biosimilar biological product (as defined in subparagraph (H) of such subsection) but excluding a qualifying biosimilar biological product (as defined in subsection (b)(8)(B)(iii)), [inserted: that] [inserted: would] [inserted: be] [inserted: payable] [inserted: under] [inserted: this part if such drug were furnished to an individual enrolled ]under this part, except such term shall not include such a drug or biological— | |||
| (2)(A)(i) | (i) | (i) | ||
| if, as determined by the Secretary, the average total allowed charges for such drug or biological under this part for a year per individual that uses such a drug or biological are less than, subject to subparagraph (B), $100; or | if, as determined by the Secretary, the average total allowed charges for such drug or biological under this part for a year per individual that uses such a drug or biological are less than, subject to subparagraph (B), $100; or | |||
| (2)(A)(ii) | (ii) | (ii) | ||
| that is a vaccine described in subparagraph (A) or (B) of section 1395x(s)(10) of this title. | that is a vaccine described in subparagraph (A) or (B) of section 1395x(s)(10) of this title. |
§ 1395w–3a(i)Rebate by manufacturers for single source drugs and biologicals with prices increasing faster than inflation(3)–(5)
(i)(2)(B)–(3) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (3)(A) | (A) In general | (A) In general | ||
| For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraphs (B) and (G) and paragraph (4), the estimated amount equal to the product of— | For purposes of paragraph (1), the amount specified in this paragraph for a part B rebatable drug assigned to a billing and payment code for a calendar quarter is, subject to subparagraphs (B) and (G) and paragraph (4), the estimated amount equal to the product of— | |||
| (3)(A)(i) | (i) | (i) | ||
| the total number of units determined under subparagraph (B) for the billing and payment code of such drug; and | the total number of [inserted: billing ]units determined under subparagraph (B) for the billing and payment code of such drug; and | |||
| (3)(A)(ii) | (ii) | (ii) | ||
| the amount (if any) by which— | the amount (if any) by which— | |||
| (3)(A)(ii)(I) | (I) | (I) | ||
| the amount equal to— | the amount equal to— | |||
| (3)(A)(ii)(I)(aa) | (aa) | (aa) | ||
| in the case of a part B rebatable drug described in paragraph (1)(B) of subsection (b), 106 percent of the amount determined under paragraph (4) of such section2 for such drug during the calendar quarter; or | in the case of a part B rebatable drug described in paragraph (1)(B) of subsection (b), 106 percent of the amount determined under paragraph (4) of such section2 for such drug during the calendar quarter; or | |||
| (3)(A)(ii)(I)(bb) | (bb) | (bb) | ||
| in the case of a part B rebatable drug described in paragraph (1)(C) of such subsection, the payment amount under such paragraph for such drug during the calendar quarter; exceeds | in the case of a part B rebatable drug described in paragraph (1)(C) of such subsection, the payment amount under such paragraph for such drug during the calendar quarter; exceeds | |||
| (3)(A)(ii)(II) | (II) | (II) | ||
| the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter. | the inflation-adjusted payment amount determined under subparagraph (C) for such part B rebatable drug during the calendar quarter. | |||
| (3)(B) | (B) Total number of units | (B) Total number of [inserted: billing ]units[inserted: .—] | ||
| For purposes of subparagraph (A)(i), the total number of | For purposes of subparagraph (A)(i), the total number of billing [inserted: units] with respect to a part B rebatable drug is [inserted: determined] [inserted: as follows:] | |||
| (3)(B)(i) | (i) | (i) | ||
| [inserted: Determine the total number of units equal to—] | ||||
| (3)(B)(i)(I) | (I) [inserted: ] | |||
| [inserted: the total number of units, as reported under subsection (c)(1)(B) for each National Drug Code of such drug during the calendar quarter that is two calendar quarters prior to the calendar quarter as described in subparagraph (A), minus] | ||||
| (3)(B)(i)(II) | (II) [inserted: ] | |||
| [inserted: the total number of units with respect to each National Drug Code of such drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A) for the rebate period that is the same calendar quarter as described in subclause (I).] | ||||
| (3)(B)(i) | ||||
| (3)(B)(ii) | (ii) | (ii) | ||
| [inserted: Convert the units determined under clause (i) to billing units for the billing and payment code of such drug, using a methodology similar to the methodology used under this section, by dividing the units determined under clause (i) for each National Drug Code of such drug by the billing unit for the billing and payment code of such drug.] | ||||
| (3)(B)(iii) | (iii) [inserted: ] | |||
| [inserted: Compute the sum of the billing units for each National Drug Code of such drug in clause (ii).] | ||||
| (3)(B)(ii) | ||||
| (3)(B)(ii)(I) | (I) | |||
| (3)(B)(ii)(II) | (II) | |||
| (3)(C) | (C) Determination of inflation-adjusted payment amount | (C) Determination of inflation-adjusted payment amount | ||
| The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is— | The inflation-adjusted payment amount determined under this subparagraph for a part B rebatable drug for a calendar quarter is— | |||
| (3)(C)(i) | (i) | (i) | ||
| the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D)); increased by | the payment amount for the billing and payment code for such drug in the payment amount benchmark quarter (as defined in subparagraph (D)); increased by | |||
| (3)(C)(ii) | (ii) | (ii) | ||
| the percentage by which the rebate period CPI–U (as defined in subparagraph (F)) for the calendar quarter exceeds the benchmark period CPI–U (as defined in subparagraph (E)). | the percentage by which the rebate period CPI–U (as defined in subparagraph (F)) for the calendar quarter exceeds the benchmark period CPI–U (as defined in subparagraph (E)). | |||
| (3)(D) | (D) Payment amount benchmark quarter | (D) Payment amount benchmark quarter | ||
| The term “payment amount benchmark quarter” means the calendar quarter beginning July 1, | The term “payment amount benchmark quarter” means the calendar quarter beginning July 1, [inserted: 2016]. | |||
| (3)(E) | (E) Benchmark period CPI–U | (E) Benchmark period CPI–U | ||
| The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January | The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January [inserted: 2016]. | |||
| (3)(F) | (F) Rebate period CPI–U | (F) Rebate period CPI–U | ||
| The term “rebate period CPI–U” means, with respect to a calendar quarter described in subparagraph (C), the greater of the benchmark period CPI–U and the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter. | The term “rebate period CPI–U” means, with respect to a calendar quarter described in subparagraph (C), the greater of the benchmark period CPI–U and the consumer price index for all urban consumers (United States city average) for the first month of the calendar quarter that is two calendar quarters prior to such described calendar quarter. | |||
| (3)(G) | (G) Reduction or waiver for shortages and severe supply chain disruptions | (G) Reduction or waiver for shortages and severe supply chain disruptions | ||
| The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part B rebatable drug and a calendar quarter— | The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part B rebatable drug and a calendar quarter— | |||
| (3)(G)(i) | (i) | (i) | ||
| in the case of a part B rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the calendar quarter; or | in the case of a part B rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the calendar quarter; or | |||
| (3)(G)(ii) | (ii) | (ii) | ||
| in the case of a biosimilar biological product, when the Secretary determines there is a severe supply chain disruption during the calendar quarter, such as that caused by a natural disaster or other unique or unexpected event. | in the case of a biosimilar biological product, when the Secretary determines there is a severe supply chain disruption during the calendar quarter, such as that caused by a natural disaster or other unique or unexpected event. | |||
| (4) | (4) Special treatment of certain drugs and exemption | (4) Special treatment of certain drugs and exemption | ||
| (4)(A) | (A) Subsequently approved drugs | (A) Subsequently approved drugs | ||
| In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after December | In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after December [inserted: 31], [inserted: 2015], clause (i) of paragraph (3)(C) shall be applied as if the term “payment amount benchmark quarter” were defined under paragraph (3)(D) as the third full calendar quarter after the day on which the drug was first marketed and clause (ii) of paragraph (3)(C) shall be applied as if the term “benchmark period CPI–U” were defined under paragraph (3)(E) as if the reference to “January [inserted: 2016]” under such paragraph were a reference to “the first month of the first full calendar quarter after the day on which the drug was first marketed”. | |||
| (4)(B) | (B) Timeline for provision of rebates for subsequently approved drugs | (B) Timeline for provision of rebates for subsequently approved drugs | ||
| In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after December | In the case of a part B rebatable drug first approved or licensed by the Food and Drug Administration after December [inserted: 31], [inserted: 2015], paragraph (1)(B) shall be applied as if the reference to “January 1, 2023” under such paragraph were a reference to “the later of the 6th full calendar quarter after the day on which the drug was first marketed or January 1, 2023”. | |||
| (4)(C) | (C) Selected drugs | (C) Selected drugs | ||
| In the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, clause (i) of paragraph (3)(C) shall be applied as if the term “payment amount benchmark quarter” were defined under paragraph (3)(D) as the calendar quarter beginning January 1 of the last year during such price applicability period with respect to such selected drug and clause (ii) of paragraph (3)(C) shall be applied as if the term “benchmark period CPI–U” were defined under paragraph (3)(E) as if the reference to “January | In the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, clause (i) of paragraph (3)(C) shall be applied as if the term “payment amount benchmark quarter” were defined under paragraph (3)(D) as the calendar quarter beginning January 1 of the last year during such price applicability period with respect to such selected drug and clause (ii) of paragraph (3)(C) shall be applied as if the term “benchmark period CPI–U” were defined under paragraph (3)(E) as if the reference to “January [inserted: 2016]” under such paragraph were a reference to “the July of the year preceding such last year”. | |||
| (5) | (5) Application to beneficiary coinsurance | (5) Application to beneficiary coinsurance | ||
| In the case of a part B rebatable drug furnished on or after April 1, 2023, if the payment amount described in paragraph (3)(A)(ii)(I) (or, in the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title), the payment amount described in subsection (b)(1)(B) for such drug) for a calendar quarter exceeds the inflation adjusted payment for such quarter— | In the case of a part B rebatable drug furnished on or after April 1, 2023, if the payment amount described in paragraph (3)(A)(ii)(I) (or, in the case of a part B rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title), the payment amount described in subsection (b)(1)(B) for such drug) for a calendar quarter exceeds the inflation adjusted payment for such quarter— | |||
| (5)(A) | (A) | (A) | ||
| in computing the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished, the computation of such coinsurance shall be equal to 20 percent of the inflation-adjusted payment amount determined under paragraph (3)(C) for such part B rebatable drug; and | in computing the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished, the computation of such coinsurance shall be equal to 20 percent of the inflation-adjusted payment amount determined under paragraph (3)(C) for such part B rebatable drug; and | |||
Rest of § 1395w–3a unchanged
42 U.S.C. § 1395w–114b Manufacturer rebate for certain drugs with prices increasing faster than inflation
10 changes the bill asks for here, 8 carried out
- Not carried out:
in subparagraph (A)(i), by striking
the total number of units
and all that follows through the semicolon and inserting the following:the total number of units that are used to calculate the average manufacturer price of such dosage form and strength with respect to such part D rebatable drug, as reported by the manufacturer of such drug under section 1927 for each month, with respect to such period;
; andWe can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking QTEXT and all that follows through the semicolon and inserting the following: QTEXT; and - Carried out:
by striking subparagraph (B) and inserting the following:
(B) Excluded units.— For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, the following: (i) Units of each dosage form and …
- Not carried out:
in paragraph (6), by striking
information.—The Secretary
and all that follows throughrebatable covered part D drug dispensed
and inserting the following:AMP reports.—The Secretary shall provide for a method and process under which, in the case of a manufacturer of a part D rebatable drug that submits revisions to information submitted under section 1927 by the manufacturer with respect to such drug
; andWe can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking QTEXT and all that follows through QTEXT and inserting the following: QTEXT; and - Carried out:
by striking subsection (d) and inserting the following:
(d) Information.— For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A)..
- Carried out:
by striking
October 1, 2021
and insertingOctober 1, 2016
; and - Carried out:
by striking
January 2021
and insertingJanuary 2016
; and - Carried out:
in subparagraph (C), by striking
January 2021
and insertingJanuary 2016
; and - Carried out:
by striking
January 1, 2021
and insertingJanuary 1, 2016
; and - Carried out:
by striking
October 1, 2021
and insertingOctober 1, 2016
; and - Carried out:
in paragraph (4), by striking
January 2021
and insertingJanuary 2016
.
§ 1395w–114b(b)(1)In general(A)–(C)
Start of § 1395w–114b to (b)(1)(A)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(ii)(I) | (I) | (I) | ||
| the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebatable drug for the period; exceeds | the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebatable drug for the period; exceeds | |||
| (A)(ii)(II) | (II) | (II) | ||
| the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebatable drug for the period. | the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebatable drug for the period. | |||
| (B) | (B) Excluded units | (B) Excluded units[inserted: .—] | ||
| [inserted: For purposes of subparagraph (A)(i), the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, the following:] | ||||
| (B)(i) | (i) [inserted: ] | |||
| [inserted: Units of each dosage form and strength of such part D rebatable drug for which payment was made under a State plan under title XIX (or waiver of such plan), as reported by States under section 1927(b)(2)(A).] | ||||
| (B)(ii) | (ii) [inserted: ] | |||
| [inserted: Units of each dosage form and strength of such part D rebatable drug for which a rebate is paid under section 1847A(i).] | ||||
| (B)(iii) | (iii) [inserted: ] | |||
| [inserted: Beginning with plan year 2026, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 340B of the Public Health Service Act.] | ||||
| (B) | ||||
| (C) | (C) Reduction or waiver for shortages and severe supply chain disruptions | (C) Reduction or waiver for shortages and severe supply chain disruptions | ||
| The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part D rebatable drug and an applicable period— | The Secretary shall reduce or waive the amount under subparagraph (A) with respect to a part D rebatable drug and an applicable period— | |||
| (C)(i) | (i) | (i) | ||
| in the case of a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the applicable period; | in the case of a part D rebatable drug that is described as currently in shortage on the shortage list in effect under section 356e of title 21 at any point during the applicable period; | |||
§ 1395w–114b(b)–(f)
(b)(1)(C)(ii)–(4)(B)(i) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(4)(B)(ii) | (ii) | (ii) | ||
| the total number of units reported under section 1396r–8 of this title of such dosage form and strength with respect to such payment amount benchmark period. | the total number of units reported under section 1396r–8 of this title of such dosage form and strength with respect to such payment amount benchmark period. | |||
| (b)(5) | (5) Special treatment of certain drugs and exemption | (5) Special treatment of certain drugs and exemption | ||
| (b)(5)(A) | (A) Subsequently approved drugs | (A) Subsequently approved drugs | ||
| In the case of a part D rebatable drug first approved or licensed by the Food and Drug Administration after October 1, | In the case of a part D rebatable drug first approved or licensed by the Food and Drug Administration after October 1, [inserted: 2016], subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term “payment amount benchmark period” were defined under subsection (g)(3) as the first calendar year beginning after the day on which the drug was first marketed and subparagraph (B) of paragraph (3) shall be applied as if the term “benchmark period CPI–U” were defined under subsection (g)(4) as if the reference to “January [inserted: 2016]” under such subsection were a reference to “January of the first year beginning after the date on which the drug was first marketed”. | |||
| (b)(5)(B) | (B) Treatment of new formulations | (B) Treatment of new formulations | ||
| (b)(5)(B)(i) | (i) In general | (i) In general | ||
| In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the rebate amount under paragraph (1) and the inflation adjusted payment amount under paragraph (3) with respect to such part D rebatable drug and an applicable period, consistent with the formula applied under subsection (c)(2)(C) of section 1396r–8 of this title for determining a rebate obligation for a rebate period under such section. | In the case of a part D rebatable drug that is a line extension of a part D rebatable drug that is an oral solid dosage form, the Secretary shall establish a formula for determining the rebate amount under paragraph (1) and the inflation adjusted payment amount under paragraph (3) with respect to such part D rebatable drug and an applicable period, consistent with the formula applied under subsection (c)(2)(C) of section 1396r–8 of this title for determining a rebate obligation for a rebate period under such section. | |||
| (b)(5)(B)(ii) | (ii) Line extension defined | (ii) Line extension defined | ||
| In this subparagraph, the term “line extension” means, with respect to a part D rebatable drug, a new formulation of the drug, such as an extended release formulation, but does not include an abuse-deterrent formulation of the drug (as determined by the Secretary), regardless of whether such abuse-deterrent formulation is an extended release formulation. | In this subparagraph, the term “line extension” means, with respect to a part D rebatable drug, a new formulation of the drug, such as an extended release formulation, but does not include an abuse-deterrent formulation of the drug (as determined by the Secretary), regardless of whether such abuse-deterrent formulation is an extended release formulation. | |||
| (b)(5)(C) | (C) Selected drugs | (C) Selected drugs | ||
| In the case of a part D rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term “payment amount benchmark period” were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph (B) of paragraph (3) shall be applied as if the term “benchmark period CPI–U” were defined under subsection (g)(4) as if the reference to “January | In the case of a part D rebatable drug that is a selected drug (as defined in section 1320f–1(c) of this title) with respect to a price applicability period (as defined in section 1320f(b)(2) of this title), in the case such drug is no longer considered to be a selected drug under section 1320f–1(c) of this title, for each applicable period (as defined under subsection (g)(7)) beginning after the price applicability period with respect to such drug, subparagraphs (A) and (B) of paragraph (4) shall be applied as if the term “payment amount benchmark period” were defined under subsection (g)(3) as the last year beginning during such price applicability period with respect to such selected drug and subparagraph (B) of paragraph (3) shall be applied as if the term “benchmark period CPI–U” were defined under subsection (g)(4) as if the reference to “January [inserted: 2016]” under such subsection were a reference to “January of the last year beginning during such price applicability period with respect to such drug”. | |||
| (b)(6) | (6) Reconciliation in case of revised information | (6) Reconciliation in case of revised information | ||
| The Secretary shall provide for a method and process under which, in the case where a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan submits revisions to the number of units of a rebatable covered part D drug dispensed, the Secretary determines, pursuant to such revisions, adjustments, if any, to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part D rebatable drug and an applicable period and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection. Any identified underpayment shall be rectified by the manufacturer not later than 30 days after the date of receipt from the Secretary of information on such underpayment. | The Secretary shall provide for a method and process under which, in the case where a PDP sponsor of a prescription drug plan or an MA organization offering an MA–PD plan submits revisions to the number of units of a rebatable covered part D drug dispensed, the Secretary determines, pursuant to such revisions, adjustments, if any, to the calculation of the amount specified in this subsection for a dosage form and strength with respect to such part D rebatable drug and an applicable period and reconciles any overpayments or underpayments in amounts paid as rebates under this subsection. Any identified underpayment shall be rectified by the manufacturer not later than 30 days after the date of receipt from the Secretary of information on such underpayment. | |||
| (c) | (c) Rebate deposits | (c) Rebate deposits | ||
| Amounts paid as rebates under subsection (b) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1395t of this title. | Amounts paid as rebates under subsection (b) shall be deposited into the Medicare Prescription Drug Account in the Federal Supplementary Medical Insurance Trust Fund established under section 1395t of this title. | |||
| (d) | (d) Information | (d) Information[inserted: .—] | ||
| [inserted: For purposes of carrying out this section, the Secretary shall use information submitted by manufacturers under section 1927(b)(3) and information submitted by States under section 1927(b)(2)(A).] | ||||
| (d)(1) | (1) | |||
| (d)(2) | (2) | |||
| (d)(3) | (3) | |||
| (e) | (e) Civil money penalty | (e) Civil money penalty | ||
| If a manufacturer of a part D rebatable drug has failed to comply with the requirement under subsection (a)(2) with respect to such drug for an applicable period, the manufacturer shall be subject to a civil money penalty in an amount equal to 125 percent of the amount specified in subsection (b) for such drug for such period. The provisions of section 1320a–7a of this title (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1320a–7a(a) of this title. | If a manufacturer of a part D rebatable drug has failed to comply with the requirement under subsection (a)(2) with respect to such drug for an applicable period, the manufacturer shall be subject to a civil money penalty in an amount equal to 125 percent of the amount specified in subsection (b) for such drug for such period. The provisions of section 1320a–7a of this title (other than subsections (a) (with respect to amounts of penalties or additional assessments) and (b)) shall apply to a civil money penalty under this subsection in the same manner as such provisions apply to a penalty or proceeding under section 1320a–7a(a) of this title. | |||
| (f) | (f) Limitation on administrative or judicial review | (f) Limitation on administrative or judicial review | ||
| There shall be no administrative or judicial review of any of the following: | There shall be no administrative or judicial review of any of the following: | |||
§ 1395w–114b(g)Definitions(2)–(6)
(f)(1)–(g)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (2) | (2) Unit | (2) Unit | ||
| The term “unit” means, with respect to a part D rebatable drug, the lowest dispensable amount (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug, as reported under section 1396r–8 of this title. | The term “unit” means, with respect to a part D rebatable drug, the lowest dispensable amount (such as a capsule or tablet, milligram of molecules, or grams) of the part D rebatable drug, as reported under section 1396r–8 of this title. | |||
| (3) | (3) Payment amount benchmark period | (3) Payment amount benchmark period | ||
| The term “payment amount benchmark period” means the period beginning January 1, | The term “payment amount benchmark period” means the period beginning January 1, [inserted: 2016], and ending in the month immediately prior to October 1, [inserted: 2016]. | |||
| (4) | (4) Benchmark period CPI–U | (4) Benchmark period CPI–U | ||
| The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January | The term “benchmark period CPI–U” means the consumer price index for all urban consumers (United States city average) for January [inserted: 2016]. | |||
| (5) | (5) Applicable period CPI–U | (5) Applicable period CPI–U | ||
| The term “applicable period CPI–U” means, with respect to an applicable period, the consumer price index for all urban consumers (United States city average) for the first month of such applicable period. | The term “applicable period CPI–U” means, with respect to an applicable period, the consumer price index for all urban consumers (United States city average) for the first month of such applicable period. | |||
| (6) | (6) Average manufacturer price | (6) Average manufacturer price | ||
| The term “average manufacturer price” has the meaning, with respect to a part D rebatable drug of a manufacturer, given such term in section 1396r–8(k)(1) of this title, with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1396r–8 of this title. | The term “average manufacturer price” has the meaning, with respect to a part D rebatable drug of a manufacturer, given such term in section 1396r–8(k)(1) of this title, with respect to a covered outpatient drug of a manufacturer for a rebate period under section 1396r–8 of this title. |
Rest of § 1395w–114b unchanged